布地奈德对嗜酸粒细胞性支气管炎患者的临床研究  

Clinical trial of budesonide in the treatment of patients with eosinophilic bronchitis

作　　者：孔育姗 谷刚[1] 田科[1] 李丽娟[2] KONG Yu-shan;GU Gang;TIAN Ke;LI Li-juan(Department of Respiratory and Critical Care,Nanhua Hospital Affiliated to Nanhua University,Hengyang 421002,Hunan Province,China;Department of Respiratory and Critical Care,Sino-Japanese Friendship Hospital,Beijing 100029,China)

机构地区：[1]南华大学附属南华医院呼吸与危重症科,湖南衡阳421002 [2]中日友好医院呼吸及危重科,北京100029

出　　处：《中国临床药理学杂志》2019年第22期2797-2800,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：目的探讨布地奈德对嗜酸粒细胞性支气管炎(EB)患者诱导痰嗜酸性粒细胞(Eos)、嗜酸性粒细胞阳离子蛋白(ECP)和效果的影响。方法将80例EB患者随机分为试验组45例,对照组35例。对照组口服孟鲁司特钠治疗,每次10mg,每天1次;试验组在对照组的基础上给予布地奈德吸入治疗,每次2 mg,每天2次。2组患者连续治疗1个月。比较2组患者的诱导痰Eos、血清ECP、白细胞介素-8(IL-8)水平、咳嗽症状积分和药物不良反应发生率。结果治疗后,试验组的诱导痰Eos、血清ECP及IL-8水平分别为(3.09±1.18)×10^9/L,(37.02±21.78)μg·L^-1,(68.92±15.71)ng·L^-1,对照组分别为(5.41±1.61)×10^9/L,(97.16±23.02)μg·L^-1,(101.99±23.87)ng·L^-1,差异均有统计学意义(P<0.05)。治疗后3 d,试验组患者的咳嗽症状缓解程度较对照组显著,而治疗后7 d与治疗后1个月相比,2组患者的咳嗽症状积分差异无统计学意义(P>0.05)。对照组药物不良反应发生率为8.60%,试验组为0,差异无统计学意义(P>0.05)。结论布地奈德联合孟鲁司特钠用于治疗EB,能显著降低患者的诱导痰Eos和血清ECP水平,抑制机体炎症反应,改善患者咳嗽症状,效果确切。Objective To explore the influence of budesonide on induction of sputum eosinophil(Eos),eosinophil cationic protein(ECP)and clinical effect in patients with eosinophilic bronchitis(EB).Methods Eighty patients with EB were randomly divided into treatment group(45 cases)and control group(35 cases).Control group was treated with montelukast sodium,10 mg/time,1 time/day,while treatment group was treated with budesonide combined with montelukast sodium,2 mg/time,2 times/day.All patients were treated continuously for one month.The levels of induction sputum Eos,serum ECP,interleukin-8(IL-8),score of cough symptoms and adverse drug reactions were compared between the two groups.Results After treatment,the levels of induction sputum Eos,serum ECP and IL-8 in treatment group were(3.09±1.18)×10^9/L,(37.02±21.78)μg·L^-1,(68.92±15.71)ng·L^-1,all had significant difference with those in control group,which were(5.41±1.61)×10^9/L,(97.16±23.02)μg·L^-1,(101.99±23.87)ng·L^-1(all P<0.05).Three days after treatment,the improvement of cough symptoms in treatment group was more obvious than that in control group(P<0.05).However,there was no significant difference in the score of cough symptoms between the two groups at 7 d after treatment and 1 month after treatment(P>0.05).The incidence of adverse drug reactions in control group and treatment group were 8.60%,0,without significant difference(P>0.05).Conclusion Budesonide combined with montelukast sodium in the treatment of EB can significantly reduce the levels of induction sputum Eos and serum ECP,inhibit the body’s inflammatory response,and improve the cough symptoms,with definite effect.

关 键 词：嗜酸粒细胞性支气管炎 嗜酸性粒细胞 嗜酸性粒细胞阳离子蛋白 布地奈德 孟鲁司特钠 

分 类 号：R974[医药卫生—药品]